AstraZeneca pays $25M upfront, $80M equity investment into Cellectis for gene and cell therapy pact
AstraZeneca is beefing up its cell and gene therapy potential by collaborating with and investing in French biotech Cellectis, starting out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
